Trials / Completed
CompletedNCT00705263
Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)
Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Slovenia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 113 (actual)
- Sponsor
- Schering-Plough · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The current gold standard for treatment of chronic hepatitis C is pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness. This is the idea behind the development and usage of the PegIntron pen (PegPen). Therefore, it is worthwhile to evaluate patients' satisfaction with this novel device. The results of the study will be used to improve PegPen training techniques for patients and health care providers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peginterferon alfa-2b (SCH 54031) | Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling. |
| DRUG | Ribavirin (SCH 18908) | Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling. |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2008-06-26
- Last updated
- 2009-08-25
- Results posted
- 2009-07-17
Source: ClinicalTrials.gov record NCT00705263. Inclusion in this directory is not an endorsement.